Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (441-450 of 551) with videos related to

Pageof 56
Sort By:
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
Lancet (London, England)|December 7, 2019
The complex challenges of HIV vaccine development require renewed and expanded global commitmentLinda-Gail Bekker, Roger Tatoud, Francois Dabis, et al.
Science (New York, N.Y.)|June 28, 2003
Medicine. The need for a global HIV vaccine enterpriseRichard D Klausner, Anthony S Fauci, Lawrence Corey, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Open Forum Infectious Diseases|March 10, 2023
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy TrialDean Follmann, Holly E Janes, Eric Chu, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.
Plos One|August 23, 2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
Pageof 56

Showing results (441-450 of 551) with videos related to

Sort By:
Pageof 56
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsAnton M Sholukh, Andrew Fiore-Gartland, Emily S Ford, et al.
Lancet (London, England)|December 7, 2019
The complex challenges of HIV vaccine development require renewed and expanded global commitmentLinda-Gail Bekker, Roger Tatoud, Francois Dabis, et al.
Science (New York, N.Y.)|June 28, 2003
Medicine. The need for a global HIV vaccine enterpriseRichard D Klausner, Anthony S Fauci, Lawrence Corey, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Open Forum Infectious Diseases|March 10, 2023
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy TrialDean Follmann, Holly E Janes, Eric Chu, et al.
The Lancet. HIV|November 28, 2025
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trialSusan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.
Plos One|August 23, 2011
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, et al.
Clinical and Vaccine Immunology : CVI|September 22, 2017
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8<sup>+</sup> T-Cell Responses by Interleukin-12 Plasmid DNAShuying S Li, Nidhi K Kochar, Marnie Elizaga, et al.
The Lancet. Infectious Diseases|July 22, 2024
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda E Gray, Kathryn Mngadi, Ludo Lavreys, et al.
Pageof 56